Overall rank by patents
#27,011
Across all tracked assignees
USPTO 2015–2025 USPTO PatentsView US Corporation
Ocunexus Therapeutics, Inc.
USPTO PatentsView assignee record - 10 granted patents across 6 technology areas, active 2019–2022. Filing-trend and competitive-moat analysis cross-referenced to USPTO Patent Public Search. Primary class: A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES).
10
Total patents granted
6
CPC technology areas
24.0
Avg claims per patent
-33%
5-year filing velocity
The verdict
Ocunexus holds 10 US patents across 6 technology areas, rank #27,011 of 50,000 tracked assignees.
- #27,011
- of 50,000 US assignees by volume
- Top 53%
- by Innovation Score (34.2/100)
- 24.0
- avg claims per patent
- -33%
- filing velocity, last 5 yrs
Portfolio overview
Ocunexus Therapeutics, Inc. has been granted 10 US utility patents between 2019 and 2022, placing Ocunexus Therapeutics, Inc. at rank #27,011 across all assignees tracked by PlainPatent. This portfolio spans 6 distinct Cooperative Patent Classification (CPC) subclasses, averaging 24.0 claims per patent with primary concentration in A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES). As a US Corporation, Ocunexus Therapeutics, Inc. is one of the more focused assignees in the PatentsView dataset. By volume, Ocunexus sits between Oberthur Fiduciaire SAS (10 patents, rank #27,007) and Okuno Chemical Industries Co., Ltd. (10 patents, rank #27,015) - the closest US assignees by grant volume. The composite Innovation Score of 34.2/100 blends portfolio volume, filing velocity, technology breadth, and claim depth into a single comparable measure drawn directly from USPTO PatentsView records.
Filing cadence tells the strategic story. Between 2020 and 2025 the company received 4 grants, compared with 6 in the 2015–2019 window, a -33% shift in five-year velocity. A cooling filing rate may reflect portfolio consolidation, shifting priorities, or reduced R&D throughput. The US Corporation classification further shapes interpretation, since corporate, government, and individual filers pursue patents for materially different reasons.
Claim depth and technology breadth together indicate competitive posture. Ocunexus Therapeutics, Inc.'s 24.0 average claims per patent reflects complex, broadly scoped inventions that are difficult for competitors to design around, while concentration in 6 subclasses points to a focused technical program. Combined with portfolio volume, these signals let analysts, investors, and licensing professionals benchmark Ocunexus Therapeutics, Inc. against peers pursuing similar technology classes.
Who files at Ocunexus's volume?
Granted US patents 2015–2025 versus its nearest-ranked assignees by volume, this company marked ◀
- Oberthur Fiduciai…
OBERTHUR FIDUCIAIRE SAS
10 patents
- Ocean Power
OCEAN POWER TECHNOLOGIES, INC.
10 patents
- OCME S R L
OCME S.R.L.
10 patents
- Oculentis Holding…
OCULENTIS HOLDING B.V.
10 patents
- ODL Incorporated
ODL, Incorporated
10 patents
- Okamoto Machine T…
OKAMOTO MACHINE TOOL WORKS, LTD.
10 patents
- Okayama Prefecture
OKAYAMA PREFECTURE
10 patents
- Okuno Chemical In…
OKUNO CHEMICAL INDUSTRIES CO., LTD.
10 patents
- Ocunexus Therapeu… ◀
OCUNEXUS THERAPEUTICS, INC.
10 patents
What this shows Ocunexus holds 10 patents at rank #27,011, shown against the 8 assignees closest to it in grant volume rather than the industry's largest filers.
Companies ranked near Ocunexus
By rank, the assignees closest to #27,011 in granted patent volume.
- Oberthur Fiduciaire SAS #27,007 · 10 patents
- Ocean Power Technologies, Inc. #27,008 · 10 patents
- OCME S.r.l. #27,009 · 10 patents
- Oculentis Holding B.v. #27,010 · 10 patents
- ODL, Incorporated #27,012 · 10 patents
- Okamoto Machine TOOL Works, Ltd. #27,013 · 10 patents
- Okayama Prefecture #27,014 · 10 patents
- Okuno Chemical Industries Co., Ltd. #27,015 · 10 patents
Leaders in A61K (Preparations FOR Medical)
Other assignees with the most granted patents in Ocunexus's primary technology class.
- The Regents Of The University Of California 1,779 in class
- L'oreal 1,250 in class
- Novartis Ag 988 in class
- The Procter & Gamble Company 985 in class
- The Board Of Regents Of The University Of Texas System 950 in class
- The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 813 in class
- The Trustees Of The University Of Pennsylvania 768 in class
- Merck Sharp & Dohme Llc 760 in class
Ocunexus's Innovation Score vs. every tracked assignee
Composite of portfolio volume, filing velocity, technology breadth, and claim depth (0–100)
34 Top 53% higher than 47% of 50,000 US assignees
Each bar is a band; taller bars hold more US assignees. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count, share, and where it sits relative to this entry.
Source USPTO PatentsView, PlainPatent Innovation Score · 2015–2025
Grants by year
Teal-shaded recent years (2020–present) versus the 2019–2019 baseline. Full figures in the table below.
View data table
| Year | Patents Granted | Share of Period |
|---|---|---|
| 2019 | 6 | 60.0% |
| 2020 | 1 | 10.0% |
| 2022 | 3 | 30.0% |
Which technologies does Ocunexus Therapeutics, Inc. patent most?
Top 6 of 6 technology areas
Patent Moat Analysis
Portfolio Volume Light
Tech Breadth Focused
Claim Depth Complex
Velocity Declining
Frequently Asked Questions
How many patents does Ocunexus Therapeutics, Inc. hold?
Ocunexus Therapeutics, Inc. holds 10 US granted patents filed between 2019 and 2022, spanning 6 technology areas.
What is Ocunexus Therapeutics, Inc.'s Innovation Score?
Ocunexus Therapeutics, Inc. has an Innovation Score of 34.2 out of 100. This composite metric weighs portfolio volume (40%), filing velocity (20%), technology breadth (25%), and claim depth (15%).
What technology areas does Ocunexus Therapeutics, Inc. focus on?
Ocunexus Therapeutics, Inc.'s top technology area is A61K (PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES) with 10 patents. The company has filed patents in 6 CPC subclasses total.
Is Ocunexus Therapeutics, Inc.'s patent filing rate increasing or decreasing?
Ocunexus Therapeutics, Inc.'s recent filing velocity is -33% compared to the prior five-year period. Filing activity has slowed relative to earlier years.
What does claim depth mean for Ocunexus Therapeutics, Inc.'s patents?
Ocunexus Therapeutics, Inc.'s patents average 24.0 claims each. This indicates complex, broadly scoped patents that are harder for competitors to design around.
How is the Ocunexus Therapeutics, Inc. patent data sourced?
All patent data comes from USPTO PatentsView, a public research dataset maintained by the United States Patent and Trademark Office covering US granted utility patents from 2015 to 2025.
How to use this portfolio
Ocunexus's 10 grants land it in the top 53% by Innovation Score, but volume alone doesn't tell you where the strength sits.
- Read that count against the largest US assignees before treating it as dominance - Ocunexus ranks #27,011 of 50,000. Top 50 holders
- Most of this portfolio concentrates in A61K - see who else leads that technology area. A61K leaders
- Check what the four-part Innovation Score actually rewards before comparing it to another company. How the score works
Patent counts and the Innovation Score measure patenting activity, not commercial success or the legal strength of any patent. Many patents are filed defensively. Verify the status of an individual patent against official USPTO records.
Every figure on PlainPatent is rendered directly from USPTO source data, no number is typed in by an editor. This page draws directly on USPTO source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of May 2026.